Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
Underlying ideological foundations of stigma and equipment inadequacy include thin-centrism and inadequate representation of fat people in health care organizational leadership.
AMA J Ethics. 2023;25(7):E528-534. doi:
10.1001/amajethics.2023.528.
Diagnostic utility of weight and body mass index is widely overestimated, and their use as health and wellness measures can be sources of iatrogenic harm.
AMA J Ethics. 2023;25(7):E540-544. doi:
10.1001/amajethics.2023.540.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.